Abstracts tagged "laboratory tests"

Abstract Number: 040 • 2023 Pediatric Rheumatology Symposium
HLA DRB1*15 and Eosinophilia Are Common Among Patients with Systemic Juvenile Idiopathic Arthritis
Alison Lerman¹, Shawn Mahmud¹, Zineb Alfath², Benjamin Langworthy³, Patricia Hobday¹, Mona Riskalla¹ and Bryce Binstadt¹, ¹Division of Pediatric Rheumatology, Allergy & Immunology, Department of Pediatrics, University of Minnesota and M Health Fairview Masonic Children’s Hospital, Minneapolis, MN, ²University of Minnesota, Minneapolis, ³Division of Biostatistics, School of Public Health and Biostatistical Design and Analysis Center, Clinical and Translational Science Institute, University of Minnesota, Minneapolis, MN
Background/Purpose: Over the last two decades, some children with systemic juvenile idiopathic arthritis (SJIA) have developed a severe form of interstitial lung disease (ILD) termed…
Abstract Number: 164 • 2018 ACR/ARHP Annual Meeting
Reliability of Lupus Anticoagulant and Anti-Phosphatidylserine/Prothrombin Autoantibodies in Antiphosphospholipid Syndrome: A Multicenter Study
Massimo Radin¹, Irene Cecchi², Elena Rubini³, Anna Scotta⁴, Roberta Rolla⁵, Barbara Montaruli⁶, Patrizia Pergolini⁵, Giulio Mengozzi⁴, Elena Muccini⁴, Antonella Vaccarino⁷, Dario Roccatello⁸ and Savino Sciascia⁹, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴University of Turin, Turin, Italy, ⁵University of Turin, Novara, Italy, ⁶Ospedale Mauriziano, Turin, Italy, ⁷Ospedale S. Giovanni Bosco, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Correct interpretation of lupus anticoagulant (LA) tests is crucial for diagnosis of antiphospholipid syndrome (APS). However, testing patients during vitamin K antagonist (VKA) or…
Abstract Number: 2321 • 2018 ACR/ARHP Annual Meeting
Dickkopf-1 Serum Levels in Patients with Systemic Sclerosis and Correlation with Trabecular Bone Score
Barbara Ruaro¹, Andrea Casabella², Sabrina Paolino¹, Carmen Pizzorni², Vanessa Smith³, Chiara Seriolo⁴, Luigi Molfetta⁴, Patrizio Odetti⁴ and Maurizio Cutolo², ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ³Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁴Centro di Ricerca su Osteoporosi e Patologie Osteoarticolari CROPO, Di.M.I., Genoa, Italy, Genoa, Italy
Background/Purpose: Dickkopf-1 (DKK1) is a natural inhibitor of Wnt signaling pathway that could be involved in promoting osteoclastogenesis through suppression of osteoprotegerin (1,2). Systemic sclerosis…
Abstract Number: 1102 • 2017 ACR/ARHP Annual Meeting
Choosing Unwisely: HLA-B27 Testing and Adherence to Choosing Wisely Practices in a Large Integrated Academic Healthcare System
Marc W. Nolan^1,2, Morgan M. Brown³ and Elie Gertner^1,2, ¹Section of Rheumatology, Regions Hospital, St. Paul, MN, ²Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ³HealthPartners Institute, St. Paul, MN
Background/Purpose: The ACR in 2013 and the Canadian Rheumatology Association (CRA) in 2015 published their respective Choosing Wisely recommendations to promote evidence-based care and reduce…
Abstract Number: 1682 • 2017 ACR/ARHP Annual Meeting
Significance of Anti-Topoisomerase I Antibodies in Routine Clinical Testing
Anne E Tebo¹, Robert L. Schmidt² and Tracy M. Frech³, ¹University of Utah, Salt Lake City, UT, ²Pathology, University of Utah, Salt Lake City, UT, ³Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: The 2013 classification criteria for systemic sclerosis (SSc) provide 3 points (towards a 9 point diagnosis) for patients who have an anti-topoisomerase I (anti-Scl-70)…
Abstract Number: 2037 • 2017 ACR/ARHP Annual Meeting
HLA-B27 Testing in Patients >= 45 Years of Age and Subsequent Diagnosis of Late Onset Spondyloarthritis
Marc W. Nolan^1,2, Morgan M. Brown³ and Elie Gertner^1,2, ¹Section of Rheumatology, Regions Hospital, St. Paul, MN, ²Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ³HealthPartners Institute, St. Paul, MN
Background/Purpose: In 2015, the Canadian Rheumatology Association published their Choosing Wisely recommendations regarding HLA-B27 testing. One of the criteria that triggers testing is inflammatory back…
Abstract Number: 1972 • 2016 ACR/ARHP Annual Meeting
Creatine Kinase in the United States Population: Impact of Demographics, Comorbidities and Body Composition on the Normal Range
Neilia-Kay McGill, Joshua F. Baker and Michael D. George, Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The accurate interpretation of creatine kinase (CK) values is critical as this laboratory measure guides the workup of suspected myopathies. Incidentally discovered CK elevation…
Abstract Number: 136 • 2015 ACR/ARHP Annual Meeting
Physician Patterns of Patient Care in Systemic Lupus Erythematosus: Are We Ordering Unnecessary Tests?
Aman Kugasia¹, Meenakshi Jolly², Winston Sequeira³, Ailda Nika³, Neha Sehgal⁴ and Mary Dollear⁵, ¹Internal Medicine, John H Stroger Hospital of Cook County, Chicago, IL, ²Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Indiana University- Bloomington, Valparaiso, IN, ⁵Vice President, Lupus Society of Illinois, Chicago, IL
Background/Purpose: To plan a quality improvement project, we need to understand the practice patterns of physicians. We undertook an online survey of physicians (MDs) (Rheumatologists,…
Abstract Number: 2120 • 2015 ACR/ARHP Annual Meeting
Alterations in Complement C3 and iC3b in SLE Pregnancies
Marta M. Guerra¹, Martin Schmidt², Elianna Kaplowitz³, Vibeke Strand⁴ and Jane E. Salmon⁵, ¹Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ²Kypha, Inc., St. Louis, MO, ³Hospital for Special Surgery, New York, NY, ⁴Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA, ⁵Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Pregnancy in patients with SLE is associated with increased risk of maternal and fetal complications. Studies in experimental models and humans suggest that complement…
Abstract Number: 2185 • 2015 ACR/ARHP Annual Meeting
Small but Clinically Insignificant Decreases in Antiphospholipid Antibody Titers Occur in aPL-Positive Patients during Pregnancy
Cécile Yelnik^1,2, Flint Porter^3,4, Ware D. Branch^3,4, Jill P. Buyon⁵, Marta Guerra⁶, Carl Laskin⁷, Michael Lockshin⁸, Michelle Petri⁹, Joan T. Merrill¹⁰, Lisa R. Sammaritano¹¹, Mary D. Stephenson¹², Mimi Y. Kim¹³ and Jane E. Salmon^11,14, ¹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ³University of Utah, Salt Lake City, UT, ⁴Intermountain Healthcare, Salt Lake City, UT, ⁵NYU School of Medicine, New York, NY, ⁶Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁷Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁸Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ⁹Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²University of Illinois College of Medicine, Chicago, IL, ¹³Albert Einstein College of Medicine, Bronx, NY, ¹⁴Hospital for Special Surgery, New York, NY
Background/Purpose: The presence of aPL has been associated with pregnancy complications, but the evolution of aPL titers during pregnancy in aPL-positive patients and the utility…
Abstract Number: 2425 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Stable Follow up Visits – 3 Month Versus 6 Month Intervals
Mark C. Fisher¹ and Deborah S. Collier², ¹Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ²Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose Specialist visits are a contributing factor to the rising cost of healthcare and payment models increasingly encourage decreased outpatient specialty visits. Due to monitoring…
Abstract Number: 2333 • 2013 ACR/ARHP Annual Meeting
Association Of Mean Changes In Laboratory Safety Parameters With C-Reactive Protein At Baseline and Week 12 In Rheumatoid Arthritis Patients Treated With Tofacitinib
V. Strand¹, J. D. Isaacs², S. Menon³, J. Beal⁴, C. I. Nduaka⁵, S. Krishnaswami³, R. Riese⁵ and M.G. Boy⁵, ¹Stanford University, Palo Alto, CA, ²Newcastle University, Newcastle-upon-Tyne, United Kingdom, ³Clinical Pharmacology, Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Changes in laboratory parameters observed during tofacitinib treatment…
Abstract Number: 2161 • 2012 ACR/ARHP Annual Meeting
Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Ethan den Boer², Maja Bulatovic³, Saskia M.F. Pluijm⁴, Johanna M.W. Hazes⁵ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Clinical Chemistry, Erasmus University Hospital, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Public Health, Erasmus Medical center, Rotterdam, Netherlands, ⁵Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 486 • 2012 ACR/ARHP Annual Meeting
Impact of Adalimumab Therapy On Laboratory Parameters of Interest in Patients with Early or Long-Standing Rheumatoid Arthritis
Daniel Furst¹, Ana P. Lacerda², Nupun Andhivarothai³, Jasmina Kalabic⁴ and Neelufar Mozaffarian³, ¹David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ²Abbott Laboratories, São Paulo, Brazil, ³Abbott Laboratories, Abbott Park, IL, ⁴Abbott GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: The systemic inflammation of rheumatoid arthritis (RA) can have detrimental effects on the hematopoietic and cardiovascular systems. Additionally, effective DMARD treatments for RA can…
Abstract Number: 468 • 2012 ACR/ARHP Annual Meeting
Adalimumab Treatment Is Associated with Decreased Concomitant Rheumatoid Arthritis Medication Use Over 24 Months
Daniel Furst¹, Neelufar Mozaffarian², Shannon Grant³, Mary Cifaldi², Jerry Clewell², Joel M. Kremer⁴ and James Shaw⁵, ¹Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ²Abbott Laboratories, Abbott Park, IL, ³Axio Research LLC, Seattle, WA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY, ⁵Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL
Background/Purpose: Adalimumab (ADA) is an effective medication in the treatment of rheumatoid arthritis (RA). However, it is not clear whether the use of ADA is associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].